Similar articles

• Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.

  Francis S, Block MJ. Francis S, et al. Arthritis Rheum. 2010 Sep;62(9):2826; author reply 2826-8. doi: 10.1002/art.27606. Arthritis Rheum. 2010. PMID: 20556822 No abstract available.
• [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].

  González-Gay MA, Agudo M. González-Gay MA, et al. Med Clin (Barc). 2010 May 22;134(15):684-5. doi: 10.1016/j.medcli.2009.12.003. Epub 2010 Feb 21. Med Clin (Barc). 2010. PMID: 20176386 Spanish. No abstract available.
• Biological disease modifying anti-rheumatic drugs.

  Cranwell-Bruce LA. Cranwell-Bruce LA. Medsurg Nurs. 2011 May-Jun;20(3):147-50. Medsurg Nurs. 2011. PMID: 21786492 No abstract available.
• [Anti-TNF therapy in rheumatoid arthritis].

  Yakeuchi T, Amano K. Yakeuchi T, et al. Nihon Rinsho Meneki Gakkai Kaishi. 2004 Feb;27(1):7-15. doi: 10.2177/jsci.27.7. Nihon Rinsho Meneki Gakkai Kaishi. 2004. PMID: 15045810 Review. Japanese. No abstract available.
• [TNF targetting therapy for rheumatoid arthritis].

  Takeuchi T. Takeuchi T. Nihon Naika Gakkai Zasshi. 2006 Sep 10;95(9):1787-94. doi: 10.2169/naika.95.1787. Nihon Naika Gakkai Zasshi. 2006. PMID: 17037316 Review. Japanese. No abstract available.